fbpx
  • About us
  • Advertise
  • Contact
  • Nominate
  • Client’s Voice
  • Login
  • Register
📖 Magazine
The Global Economics
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
The Global Economics
No Result
View All Result
Home Infrastructure Healthcare

WHO accepts Mosquirix vaccine on 6th Oct for Malaria infected children

The Mosquirix vaccine is anticipated to prevent Malaria and save numerous young lives every year

Sakshi K S by Sakshi K S
October 8, 2021
in Healthcare, The Global Economics, Top Stories
Reading Time: 2 mins read
0
WHO accepts Mosquirix vaccine on 6th Oct for Malaria infected children

WHO accepts Mosquirix vaccine on 6th Oct for Malaria infected children

597
SHARES
3.3k
VIEWS
FacebookTwitterRedditWhatsAppLinkedInShare Link

The World Health Organization (WHO) stated on 6th Oct (Wednesday) that the solely accepted vaccine against malaria must be broadly given to African children, establishing the most important advancement against the disease that has killed thousands of people every year.

World Health Organization recommends Mosquirix for Malaria infected African children

The World Health Organization recommends RTS,S, retailed as ‘Mosquirix’, a vaccine produced by GlaxoSmithKline (GSK), a British drugmaker.

Approximately 2.3 million doses of Mosquirix, since 2019, have been directed to newborns in Malawi, Kenya, and Ghana in an extensive scale pilot program synchronized by the World Health Organization. Majorly, children below the age of 5 are the victims of Malaria’s fatal conclusion.

The Mosquirix vaccine program is followed after 10 years of clinical tests in 7 African nations.

Tedros Adhanom Ghebreyesus, WHO Director-General, stated that the most anticipated Malaria vaccine Mosquirix is a milestone for the domain of science.

The Mosquirix vaccine is anticipated to prevent Malaria and save numerous young lives every year, Ghebreyesus stated.

In Africa, Malaria is a deadlier disease than COVID19. In 2019, the former has already proven to be fatal to 386,000 Africans, according to a WHO estimate. COVID19 deaths dwindled at 212,000 deaths in the past 1.5 years, according to WHO.

The WHO stated that 94% of Malaria deaths and calamities occur in Africa, a mainland that houses 1.3 billion people. The curable disease is caused by infected mosquito bites that transmit parasites to people and instills Malaria symptoms that include fatigue, vomiting, and fever.

The Mosquirix vaccine’s efficiency at fighting critical cases of Malaria in children is estimated to be around 30%. However, even with such a low-efficiency percentage, the Mosquirix vaccine is the only accepted vaccine as its benefits overshadow hazards.

Scientists at the United Kingdom’s University of Oxford have developed another vaccine against Malaria. The R21/Matrix-M has shown around 77% efficiency in a study that involved 450 children from Burkina Faso. However, researchers have indicated that the legitimacy of the vaccine is still not established as it is in the trial stages.

The challenge of funds

GSK has committed to manufacturing 15 million doses of the Mosquirix vaccine every year. Additionally, 10 million doses have been donated to the WHO trial programs, till 2028, with a fee for the production and a 5% margin.

The demand for a malaria vaccine is estimated to be 50 to 110 million doses annually by 2030 in areas of high transmission rates, according to a WHO global market study.

A global public-private partnership, the GAVI vaccine alliance, will decide in December about the medium and whether to finance the Mosquirix vaccination program.

Director of WHO’s Department of Immunization, Vaccines & Biologicals, Kate O’Brien, stated that political will is the medium through which funds will be available to facilitate a large-scale production and distribution of the Mosquirix vaccine.

A source closely associated with the planning of the Mosquirix vaccine development stated that the price for every dose was not yet established. However, vaccine prices can be confirmed following GAVI’s funding decision and once the demand for the vaccine is established.

BioNTech, a German biotechnology company, developed the COVID19 vaccine against Pfizer, a US mogul. The former stated that it targeted to begin tests for a Malaria vaccine in 2022 using the identical mRNA technology.

The WHO is also hoping for more scientists to emerge with developments for Malaria vaccines.

Via: Short URL
Tags: African childrenMalaria vaccineMosquirixWorld Health Organization
Sakshi K S

Sakshi K S

Sakshi is a professional content writer engaging readers with gripping business news stories.

Related Posts

HSBC To Shift Focus From West To Asia Pacific
Commercial

HSBC To Shift Focus From West To Asia Pacific

by The Global Economics
May 26, 2023
Repercussions of the United States Defaulting on its debt
Economy

Repercussions of the United States Defaulting on its debt

by The Global Economics
May 25, 2023
Singapore’s OCBC Bank and ADDX launch tokenised structure notes through a strategic partnership
Top Stories

Singapore’s OCBC Bank and ADDX launch tokenised structure notes through a strategic partnership

by Riya Thomas
May 25, 2023
Pan Asia and VinES Sign a Deal to Research on Lithium Conversion Facility
Energy

Pan Asia and VinES Sign a Deal to Research on Lithium Conversion Facility

by The Global Economics
May 25, 2023
Is the Micron Chip Ban an Indication of Intensifying Sino-US Trade Conflict?
Technology

Is the Micron Chip Ban an Indication of Intensifying Sino-US Trade Conflict?

by Riya Thomas
May 24, 2023
Previous slide
Next slide
Facebook Twitter Instagram Youtube LinkedIn Soundcloud
The Global Economics

The Global Economics Limited is a UK based financial publication and a quarterly business magazine giving thoughtful insights into the financial sectors on various industries across the world. Our highlight is the prestigious country specific Annual Global Economics awards program where the best performers in various financial sectors are identified worldwide and honoured.

DMCA.com Protection Status

  • Privacy
  • Legal
  • Terms of Use
  • Client’s Voice
  • Server Status

norton verified - the global economics

Latest Posts

Qred Emerges as Europe's Newest Bank

Qred Emerges as Europe’s Newest Bank

May 29, 2023
Shein Intends to Build a Mexico Factory

Shein Intends to Build a Mexico Factory

May 29, 2023
HSBC To Shift Focus From West To Asia Pacific

HSBC To Shift Focus From West To Asia Pacific

May 26, 2023
Download The Global Economics PWA to your mobile or Desktop
PWA App Download
Download The Global Economics Android App to your mobile or Desktop
Android App
Download The Global Economics IOS App to your mobile or Desktop
IOS App

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

No Result
View All Result
  • About us
  • Awards
  • Magazine
  • Client’s Voice
  • Exclusive Coverage
  • Nominate
  • Login
  • Sign Up

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

Welcome Back!

Sign In with Facebook
Sign In with Linked In
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Linked In
OR

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
-
00:00
00:00

Queue

Update Required Flash plugin
-
00:00
00:00
Go to mobile version